ROS1 fusions were identified as potential driver mutations in an NSCLC cell line (HCC78; SLC34A2-ROS1) and an NSCLC-patient sample (CD74-ROS1) in a large-scale survey of tyrosine kinase activity in lung cancer using phosphoproteomic approaches [103]. Here, SLC34A2 is linked to non-small cell lung carcinoma.